BioSpace News Archive

Spero Therapeutics, Inc. (Nasdaq: SPRO), today announced topline findings from its Phase 1 bronchoalveolar lavage (BAL) clinical trial of SPR206.

CytomX Therapeutics, Inc. announced that on February 16, 2022, the Company granted nine new employees options to purchase a total of 189,400 shares of the Company’s common stock at an exercise price per share equal to $4.08, which was the closing trading price on February 15, 2022, the date of the grant.

Dyve Biosciences, Inc. today announced that company management will be presenting a corporate overview and participating in 1-on-1 meetings at the 32nd Annual Oppenheimer Healthcare Conference taking place virtually March 15 - 16, 2022.

Rhythm Pharmaceuticals, Inc. today announced positive interim data from its long-term extension study evaluating setmelanotide in patients with Bardet-Biedl Syndrome (BBS).

Accolade, Inc. (NASDAQ: ACCD), a healthcare provider that serves over 600 employers and millions of members, will participate in the 2022 SVB Leerink Global Healthcare Conference, including a fireside chat presentation on Friday, February 18, 2022 at 2:20 p.m. E.T.

Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Monday, February 28, 2022 at 5:00 PM ET to report its fourth quarter and full year 2021 financial results and provide a corporate update.

BriaCell Therapeutics Corp. announces the appointment of Giuseppe Del Priore, MD, MPH, as the Company’s Chief Medical Officer (CMO), effective today.

BioVaxys Technology Corp. announced today that studies on BVX-0320, its haptenized SARS-CoV-2 s-spike protein vaccine, demonstrate that the vaccine does not bind to the Angiotensin Converting Enzyme-2 (ACE2) receptor.

Theranica, today announced the publication of a new peer-reviewed study published in Pain Medicine, examining the use of combining Nerivio’s® Guided Imagery, Education and Relaxation (GIER) in-app optional behavioral intervention feature for acute treatment of migraine.

Today, CELLINK, a BICO Group company (Nasdaq Stockholm: BICO) and a global leader in developing 3D bioprinting technologies which is expected to bridge the current gap and allow unlimited supply of life saving organs and CollPlant Biotechnologies (Nasdaq: CLGN) announced they have signed a collaboration agreement.